Windlas Biotech Limited's Board of Directors has approved a significant share buyback program worth ₹47 crore, demonstrating the company's commitment to returning value to shareholders. The decision was made during a board meeting held on April 17, 2026, with the record date set for April 24, 2026.

Buyback Program Details

The board approved the buyback of up to 4,70,000 fully paid-up equity shares, each with a face value of ₹5.00. The buyback will be conducted at ₹1,000 per equity share, payable in cash, for a total amount not exceeding ₹47 crore.

Regulatory Compliance and Structure

The buyback represents 9.80% of the aggregate total paid-up equity share capital and free reserves based on the company's latest audited standalone and consolidated financial statements as of March 31, 2025. The program will be conducted through the tender offer route as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

Notably, promoters and members of the promoter group have indicated their intention not to participate in the proposed buyback. The company will reserve 15% of the buyback shares for small shareholders, whichever is higher between this percentage or the number of shares entitled based on small shareholders' holdings on the record date.

Current Shareholding Pattern

As of March 31, 2026, the company's pre-buyback shareholding structure shows a diverse investor base across multiple categories:

Implementation and Management

The board has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Mr. Ananta Narayan Panda, Company Secretary, has been appointed as the Compliance Officer for the proposed buyback. Fintellectual Corporate Advisors Private Limited, a SEBI registered merchant banker, will serve as the Manager to the Buyback.

The board retains flexibility to increase the buyback price and decrease the number of equity shares proposed for buyback until one working day prior to the record date, provided there is no change in the aggregate buyback size. A public announcement and letter of offer detailing the complete process, timelines, and other requisite details will be released in accordance with SEBI Buyback Regulations.

Next Steps

Shareholders as of the record date of April 24, 2026 will be eligible to participate in the buyback program. The post-buyback shareholding pattern will be determined after completion of the buyback process. The buyback size excludes transaction costs such as brokerage, fees, taxes, and other incidental expenses related to the process.

Windlas Biotech Limited has successfully concluded its Board of Directors meeting held on April 17, 2026, approving a comprehensive share buyback proposal worth ₹470 crore. The pharmaceutical company announced the outcome through regulatory filings to stock exchanges under Regulation 30 and Regulation 42 of SEBI LODR Regulations, marking a significant corporate action for shareholders.

Buyback Approval Details

The board has approved the buyback of up to 4,70,000 fully paid-up equity shares, each having a face value of ₹5.00, representing 2.23% of the total equity shares in the existing paid-up equity share capital. The buyback will be conducted at a price of ₹1,000 per equity share, payable in cash, representing 9.80% of the aggregate total paid-up equity share capital and free reserves based on audited financial statements as at March 31, 2025.

Record Date and Regulatory Framework

Pursuant to Regulation 42 of SEBI LODR Regulations and Regulation 9(i) of SEBI Buy-Back Regulations, Friday, April 24, 2026, has been fixed as the record date for determining shareholder eligibility. The buyback will be conducted through the "Tender Offer" route as prescribed under SEBI Buy-Back Regulations, 2018, with 15% of the buyback quantity reserved for small shareholders.

Current Shareholding Pattern

As of March 31, 2026, the company's pre-buyback shareholding structure shows promoters and promoter group holding 1,30,65,352 shares representing 61.90% of the total paid-up capital. The total number of shareholders stands at 44,769 with 2,11,06,229 equity shares outstanding.

Management and Compliance Structure

The board has constituted a buyback committee with delegated powers to execute all necessary actions for the buyback process. Mr. Ananta Narayan Panda, Company Secretary, has been appointed as the Compliance Officer for the proposed buyback. Fintellectual Corporate Advisors Private Limited, a SEBI registered merchant banker, has been appointed as the Manager to the Buyback.

The promoters and members of the promoter group have indicated their intention not to participate in the proposed buyback. The board retains flexibility to increase the buyback price and decrease the number of shares till one working day prior to the record date, ensuring no change in the aggregate buyback size. The public announcement and letter of offer detailing the complete process, timelines, and other requisite details will be released in accordance with SEBI Buyback Regulations.